Web7 apr. 2024 · A Randomized Phase III Non-inferiority Trial Assessing Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or … Web30 iul. 2024 · Role of Consolidation. Consolidation therapy is generally defined as treatment given for a short duration (i.e., 2 to 4 cycles), usually with the same regimen used for …

TriNetX Publishes European Multiple Myeloma Real-World …

Web16 apr. 2024 · Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma Nisha S. Joseph, MD1 ; Jonathan L. Kaufman, MD1 ; Madhav V. Dhodapkar, MD1 ; Craig C. Hofmeister, MD, MPH1 ; Dhwani K. Almaula, … Web20 apr. 2024 · The current management of multiple myeloma is based upon eligibility for autologous stem cell transplantation (ASCT). Patients who are transplant-eligible (age ≤ … sangle top tether

Induction Therapy in Multiple Myeloma - HealthTree for Myeloma

Web8 apr. 2024 · Multiple Myeloma (MM) remains a difficult to treat disease mainly due to its biological heterogeneity, of which we are more and more knowledgeable thanks to the development of increasingly sensitive molecular methods that allow us to build better prognostication models. The biological diversity translates into a wide range of clinical … Web21 ian. 2024 · Darzalex vs. Sarclisa for Multiple Myeloma. While there is debate about whether to add a fourth drug to the induction therapy regimen, there is also debate about which monoclonal antibody drug is best to use in … Web14 apr. 2024 · Objective: To investigate the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). Methods: We … sangle wintec cair